Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7917646 | 0.83 | CA1 (0.42) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL24458009 | 0.82 | TSHR (0.37) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL10601532 | 0.82 | CA9 (0.37) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL3645882 | 0.81 | ALDH1A1 (0.48) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL722597 | 0.81 | BCAT2 (0.44) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL135801 | 0.81 | CA1 (0.60) | CA1CA2CA9MMP1MMP2 | |
| SCHEMBL6631818 | 0.81 | BCAT2 (0.62) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL30455577 | 0.81 | BCAT2 (0.62) | BCAT2CA1CA2CA9CA5A | |
| Hydrochloric Acid SCHEMBL7552816 | 0.79 | BCAT2 (0.43) | BCAT2CA1CA2CA9CA5A | |
| SCHEMBL2511276 | 0.79 | CA1 (0.65) | BCAT2CA1CA2CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| CN-111494380-B | Application of DB-1 in preparation of medicine for preventing and treating NLRP3 inflammation body related diseases and pharmaceutical composition thereof | 中国药科大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-111494380-A | Application of DB-1 in preparation of medicine for preventing and treating N L RP3 inflammasome-related diseases and pharmaceutical composition thereof | 中国药科大学 | 2020-08-07 | — | — | CN | disclosed |
| CN-108164503-B | A kind of heteroaromatic and the disubstituted benzenesulfonamides of alkyl side chain and its preparing the application in anti-influenza A virus medicament | 武汉大学 | 2019-09-17 | — | — | CN | disclosed |
| CN-106279167-B | Matrine compound derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2018-11-13 | — | — | CN | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| CN-108164503-A | A kind of heteroaromatic and the disubstituted benzenesulfonamides of alkyl side chain and its application in anti-influenza A virus medicament is prepared | 武汉大学 | 2018-06-15 | — | — | CN | disclosed |
| CN-106905319-A | The preparation method of substitution benzene sulfonyl kuh-seng butane or its hydrochloride | 中国医学科学院医药生物技术研究所 | 2017-06-30 | — | — | CN | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004073634-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2002051410-A2 | PHENYLTHIAZOLE AND THIAZOLINE DERIVATIVES AND THEIR USE AS ANTIPARASITICS | AKZO NOBEL N.V. (NL) | 2002-07-04 | — | — | WO | disclosed |
| EP-0613468-B1 | Substituted salicylic acids for the treatment of autoimmune diseases | PHARMACIA & UPJOHN AB (SE) | 2000-07-12 | — | — | EP | disclosed |
| US-5556855-A | TREATMENT OF AUTOIMMUNE DISEASES | PHARMACIA AB (SE) | 1996-09-17 | — | — | US | disclosed |
| US-5403930-A | Chemical intermediate for drugs used in autoimmune diseases | PHARMACIA AB (SE) | 1995-04-04 | — | — | US | disclosed |
| EP-0613468-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | Pharmacia & Upjohn Aktiebolag (SE) | 1994-09-07 | — | — | EP | disclosed |
| US-5302718-A | Used for treating autoimmune diseases | KABI PHARMACIA AB (SE) | 1994-04-12 | — | — | US | disclosed |
| WO-1993010094-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | KABI PHARMACIA AB (SE) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | BCAT2 1826/4885CA1 2141/4885CA2 1262/4885 |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | BCAT2 1147/4885CA1 1741/4885CA2 1885/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | BCAT2 270/4885CA1 3845/4885CA2 4141/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | BCAT2 1826/4885CA1 2141/4885CA2 1262/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | BCAT2 1147/4885CA1 1741/4885CA2 1885/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | BCAT2 270/4885CA1 3845/4885CA2 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.